Rohkem informatsiooni ― Eesti keel

On teada, et Q-switched Nd:YAG laser ravib tõhusalt Ota nevus ja sarnaseid haigusi. Viisime läbi uuringu, et näha, kui hästi töötas high-fluence 1064 nm Q-switched Nd:YAG laser Mongoolia täppidel ebatavalistes piirkondades, põhjustamata naha heledamaks muutmist. Uurisime 61 nende laikudega patsienti, uurides kokku 70 kahjustust. Pooli kahjustustest raviti laseriga, teised aga jäeti võrdluseks ravimata. Hindasime tulemusi, kasutades melaniini taseme mõõtmiseks skaalat ja seadet nimega Mexameter®. Patsiente jälgiti ravirühmas keskmiselt 14 kuud ja vaatlusrühmas 18 kuud. Uuringu lõpus leidsime olulisi erinevusi skaala skoorides ja melaniini tasemetes ravitud ja ravimata rühmade vahel, kusjuures laseriga töödeldud rühm näitas paremaid tulemusi. High-fluence Q-switched Nd:YAG laser osutus nende ebatavaliste Mongoolia laikude ravimisel tõhusaks ja ohutuks, põhjustamata naha heledamaks muutmist.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.

Uurisime konkreetse laserravi kasutamise tõhusust ja ohutust ABNOM jaoks ning uurisime, millised tegurid võivad selle toimimist mõjutada. Vaatasime 110 patsienti, kellel oli ABNOM ja kes said kaks kuni üheksa laserravi. Leidsime, et ravi toimis paremini, mida kauem seda tehti, kuid mitte nii hästi vanematel patsientidel. See toimis paremini ka heledama nahaga (III tüüp) ja väiksemate kahjustatud piirkondadega (alla 10 cm2) patsientidel. Melasma koos ABNOM -ga muutis ravi vähem tõhusaks. Mõjutatud piirkondade värvus või arv ei paistnud muutvat. Umbes 10% patsientidest tekkisid pärast ravi tumedamad laigud. Varajane mitmekordne ravi andis häid tulemusi. Vanematel patsientidel, kellel on tumedam nahk ja tumedamad laigud, tekivad pärast ravi suurema tõenäosusega tumedamad laigud. ABNOM ja melasmaga patsientidel on parem kasutada madalama energiatarbega laserit, et vältida melasma süvenemist.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.